Malaysia Device Grouping Rules: Single, Family, System and Set

1. Key takeaways

Grouping is the mechanism by which several products are filed under a single registration application and recorded in the Malaysia Medical Device Register (MMDR). The Second Schedule to the Medical Device Regulations 2012 permits it, and the forms it recognises are Single, Family, System and Set, with the IVD Test Kit and the IVD Cluster additionally available where the product is an in vitro diagnostic. Grouping is not a filing convenience that can be arranged after the fact. It changes the scope of the certificate, the number of applications, the fee total and the way a later change or a field action is handled, so the grouping decision belongs at the start of the project rather than at the point of submission.

• Grouping is authorised by the Second Schedule and results in one registration entry in the MMDR covering more than one product.
• Four forms apply to general devices, namely Single, Family, System and Set; for IVDs the IVD Test Kit and the IVD Cluster are available as well.
• Three conditions must be satisfied at the same time: one generic proprietary name, one manufacturer, and one common intended purpose.
• A group company may treat its headquarters as the manufacturer, which allows subsidiaries and regional manufacturing sites to be covered by the same grouping analysis.
• Official fees are charged per registration application under the Fifth Schedule, so the grouping structure determines how many applications attract a fee.
• Products of different risk classes must not be forced into one group to save fees, and where a group is used the classification logic is set by the highest risk in the group and has to be argued in advance.

2. Legal basis

The Second Schedule to the Medical Device Regulations 2012 sets out the grouping rules. Its function is to define when several products may be treated as one registration rather than several, and it does so by reference to identity of name, identity of manufacturer and identity of purpose. The three conditions are cumulative rather than alternative. A product family that shares a name and a manufacturer but serves two different intended purposes cannot be grouped, and neither can two products with the same purpose from different manufacturers, even where one is a contract manufacturer for the other, unless the group structure allows the headquarters to be treated as the manufacturer.

The manufacturer condition is the one that requires the most careful reading in a corporate group. The rule permits a group company to treat its headquarters as the manufacturer, which brings subsidiaries and regional manufacturing sites within reach of a single grouping analysis. This is useful for groups that manufacture the same product in more than one country, but it depends on the corporate relationship being documented. Where the relationship is a distribution arrangement rather than a group structure, the headquarters treatment is not available and the products remain separate.

The proprietary name condition is a condition about one generic proprietary name, not about brand variants that happen to sound alike. The intended purpose condition is a condition about one common purpose, not about purposes that overlap. Each condition should be evidenced in the grouping rationale rather than asserted, because the grouping is visible in the register and can be questioned at review or later, when a change to one member of the group is notified.

Fees follow the grouping structure because they are charged per registration application under the Fifth Schedule. A well-constructed grouping reduces the number of applications without changing the substance of what is assessed, and therefore reduces the fee total legitimately. What the framework does not permit is the use of grouping to compress products of different risk classes into one entry for the purpose of paying less. Where a group is used, the class applied is the highest risk represented in the group, and that consequence has to be reasoned through before the group is formed rather than discovered when the fee is calculated.

3. Expert insights

The commercial logic of grouping is straightforward: fewer applications mean fewer dossiers, fewer review cycles and a lower fee total. The regulatory logic is less obvious and more important. A group creates a shared fate. If one member of the group is the subject of a field safety corrective action, the entry through which it is registered is the entry affected, and the visibility of the group extends to every product recorded under it. Grouping decisions should therefore be taken with a view to how the products will be supported after registration, not only to how they will be filed.

For manufacturers with many stock keeping units, the practical technique is to build a grouping matrix before any dossier work begins. The matrix lists each product against the three conditions, records the intended purpose in a single standard sentence, and marks the class. Products that satisfy all three conditions and share a class fall into a candidate group; products that fail any condition are separated immediately. Done at this stage, the exercise prevents the most expensive error in grouping, which is discovering during review that two products in one application do not share a common intended purpose and having to split an application that has already been assessed.

The IVD forms require their own analysis. The IVD Test Kit and the IVD Cluster are designed for situations such as combined testing of multiple analytes and multiple reagents on a single platform, and the boundary between what may be included and what must be filed separately is a matter for the MDA IVD grouping guidance rather than for inference from the general rules. Manufacturers sometimes assume that reagents sold together in a box are automatically one kit, which is not the same question as whether they may be grouped, and the two questions should be kept apart.

As a matter of practical estimate, drawn from industry experience rather than from any official figure, a considered grouping exercise on a multi-SKU portfolio can reduce filing workload by 20% to 40%. The figure is indicative only and depends on the MDA accepting the grouping, so it should be used for planning and not for commitments to management or to customers.

4. Practical recommendations

• Build the grouping matrix before drafting any dossier, testing every product against the three conditions and recording the result for each.
• Write one standard intended purpose sentence per candidate group and use it consistently in labelling, the technical file and the application.
• Document the corporate relationship where headquarters treatment is relied on to cover subsidiaries or regional manufacturing sites.
• Keep products of different classes out of the same group, and where a group is unavoidable, argue the highest-risk classification explicitly before submission.
• Confirm IVD grouping against the MDA IVD grouping guidance rather than against the general rules, treating kit composition and grouping eligibility as separate questions.
• Plan the post-registration support of each group as a unit, since a field action on one member will be handled through the entry that covers them all.

5. Verification checklist

• □ Second Schedule to the Medical Device Regulations 2012 read in full for the grouping definitions (pending verification, as at 19 October 2026).
• □ MDA Guidance Document on Grouping of Medical Device reviewed in its current edition (pending verification).
• □ MDA website page on grouping for general medical devices checked for the current form definitions (pending verification).
• □ MDA IVD registration training materials of 2023 reviewed for the IVD Test Kit and IVD Cluster boundaries (pending verification).
• □ Fee total recalculated on the number of applications produced by the proposed grouping, against the Fifth Schedule (pending verification).
• □ Grouping rationale recorded in writing, with the three conditions addressed individually for each member (pending verification).

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Malaysia. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the MDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com